Lummy Strikes First Deal Under VC Fund Investment
This article was originally published in PharmAsia News
Executive Summary
TVM Capital Life Science has established a new $50 million venture capital fund with investment from Chinese partner Lummy, which has already tapped the new vehicle for a licensing deal for an oncology dendritic vaccine.